DcR3、CA19-9联合检测在胰腺癌诊断中的临床价值

Clinical value of combined detection of serum decoy receptor 3 and CA19-9 in diagnosis of pancreatic cancer

目的:探讨血清中诱骗受体3(decoy receptor3,DcR 3)和CA19-9联合检测对胰腺癌诊断的临床价值.方法:收集90例胰腺癌、20例胰腺良性肿瘤患者及20例健康对照者血清,应用酶联免疫吸附试验(ELISA)方法测定Dc R3水平,电化学发光免疫分析法测定血清CA19-9水平,采用受试者工作特征(receiver operating characteristic,ROC)曲线评估他们对胰腺癌诊断和可切除性判断的临床价值.结果:胰腺癌患者血清Dc R3和CA19-9水平分别为37.75 pg/m L和202.29 k U/L,明显高于胰腺良性肿瘤组和健康对照组,差异均有统计学意义(P<0.01).Dc R3和CA19-9诊断胰腺癌的曲线下面积(area under ROC curves,A U C)分别为0.81和0.89,两者联合检测的A U C为0.95.D c R3和C A19-9对胰腺癌科切除性判断的AUC分别为0.68和0.59,两者联合检测的AUC为0.73.结论:Dc R3和CA19-9在胰腺癌患者血清中升高,两者联合检测有助于提高胰腺癌诊断价值和可切除性的判断.

AIM：To assess the clinical value of combined detection of serum decoy receptor 3（DcR3） and CA19-9 in the diagnosis of pancreatic cancer.METHODS：Serum samples were collected from90 pancreatic cancer patients,20 pancreatic benign tumor patients and 20 healthy persons.Serum DcR3 levels were detected by ELISA,and serum CA19-9 levels were detected by eletro-chemiluminescent immunoassay.The receiver operating characteristic（ROC） curve was constructed to evaluate the diagnostic value and predict the resectability of pancreatic cancer.RESULTS：The median serum levels of DcR3 and CA19-9 were 37.75 pg/mL and 202.29 kU/L,respectively,in the pancreatic cancer group,and they were significantly higher than those in patients with benign tumors or healthy persons（P 〈 0.01 for both）.The area under ROC curves（AUC） of DcR3 and CA19-9 were 0.81 and 0.89,respectively,and AUC of combined detection of two markers produced the highest diagnostic yield（AUC = 0.95）.For predicting resectability of pancreatic cancer,AUC values of DcR3 and CA19-9 were 0.68 and 0.59,respectively,however,AUC of combined detection of the two markers was 0.73.CONCLUSION：The levels of serum DcR3 and CA19-9 are significantly elevated in pancreatic cancer patients.The combined detection of DcR3 and CA19-9 may be helpful to the diagnosis and predicting resectability of pancreatic cancer.